

"A Phenotypic Screening Technology Aimed at Drugging Undruggable Targets"



Chris Torrance, PhD CEO and Co-Founder, PhoreMost Ltd. Cambridge, UK

Tuesday, February 23, 2016 2PM Location: Yawkey 308